US 11,986,493 B2
Inorganic nitrite to improve cardiopulmonary hemodynamics
Mark Thomas Gladwin, Pittsburgh, PA (US); Edwin Parsley, Houston, TX (US); and Hunter Clay Champion, Midland, GA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US); and Aires Pharmaceuticals, Inc., San Diego, CA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Dec. 2, 2021, as Appl. No. 17/540,965.
Application 17/540,965 is a continuation of application No. 15/954,304, filed on Apr. 16, 2018, granted, now 11,219,640.
Application 15/954,304 is a continuation of application No. 14/768,198, abandoned, previously published as PCT/US2014/019703, filed on Feb. 28, 2014.
Claims priority of provisional application 61/771,063, filed on Feb. 28, 2013.
Prior Publication US 2022/0088065 A1, Mar. 24, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/00 (2006.01); A61K 9/00 (2006.01); A61K 31/04 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 9/007 (2013.01); A61K 9/0073 (2013.01); A61K 31/04 (2013.01)] 16 Claims
 
1. A method of decreasing one or more of pulmonary capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure in a subject, relative to the subject's capillary wedge pressure, right atrial pressure, and pulmonary arterial pressure, respectively, at the start of administration, comprising administering, by inhalation, a therapeutically effective dose of inorganic nitrite in an escalated titrated dose, wherein such administration does not cause a significant drop in systemic blood pressure and increase in heart rate.